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The membrane phospholipid phosphatidylinositol 4, 5-bisphosphate [PI(4,5)P
 
2
 
] is a critical 
signal transducer in eukaryotic cells. However, the physiological roles of the type I 
phosphatidylinositol phosphate kinases (PIPKIs) that synthesize PI(4,5)P
 
2
 
 are largely unknown. 
Here, we show that the 
 
 
 
 isozyme of PIPKI (PIPKI
 
 
 
) negatively regulates mast cell functions 
and anaphylactic responses. In vitro, PIPKI
 
 
 
-deficient mast cells exhibited increased 
degranulation and cytokine production after Fc
 
 
 
 receptor-I cross-linking. In vivo, 
 
PIPKI
 
 
 
   
 
 
mice displayed enhanced passive cutaneous and systemic anaphylaxis. Filamentous actin was 
diminished in 
 
PIPKI
 
 
 
   
 
 mast cells, and enhanced degranulation observed in the absence of 
PIPKI
 
 
 
 was also seen in wild-type mast cells treated with latrunculin, a pharmacological 
inhibitor of actin polymerization. Moreover, the association of Fc
 
 
 
RI with lipid rafts and 
Fc
 
 
 
RI-mediated activation of signaling proteins was augmented in 
 
PIPKI
 
 
 
   
 
 mast cells. 
Thus, PIPKI
 
 
 
 is a negative regulator of Fc
 
 
 
RI-mediated cellular responses and anaphylaxis, 
which functions by controlling the actin cytoskeleton and dynamics of Fc
 
 
 
RI signaling. 
Our results indicate that the different PIPKI isoforms might be functionally specialized.
 
Engagement of mast cell Fc
 
 
 
RI by IgE, fol-
lowed by the aggregation of multiple IgE-
bearing Fc
 
 
 
RI molecules by polyvalent antigen,
leads to cellular activation and the initiation of
allergic reactions (1–3). Activated mast cells
release preformed granule-associated chemical
mediators, transcribe multiple cytokine genes,
and secrete newly synthesized arachidonic acid
metabolites and various proteins that trigger
allergic inflammation. At the molecular level,
the cross-linking of mast cell Fc
 
 
 
RI molecules
initiates various signaling cascades that lead
to the generation of second messengers, pro-
tein phosphorylation, and protein–protein and
lipid–protein interactions (4). Among the most
important intracellular signaling molecules acti-
vated after Fc
 
 
 
RI cross-linking are the phos-
pholipid-metabolizing enzymes, which include
phospholipase C (PLC; reference 5), src ho-
mology 2-containing inositol 5-phosphatase 1
(6), and the phosphoinositide 3-kinases (PI3Ks;
references 7, 8).
Phosphorylated derivatives of phosphati-
dylinositol, collectively referred to as phospho-
inositides, make up a minor proportion of
membrane phospholipids, but are important
intermediates in eukaryotic cellular responses
(9, 10). Two major second messengers, phos-
phatidylinositol 3, 4, 5-trisphosphate (PIP
 
3
 
)
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and inositol 1,4,5-trisphosphate (IP
 
3
 
), are produced by PI3Ks
and PLC, respectively. PIP
 
3
 
 and IP
 
3
 
 are required for intracel-
lular signal transduction pathways activated by most cell sur-
face receptors, including cytokine/growth factor receptors,
the T cell receptor, the B cell receptor, and receptors for Ig.
There is increasing evidence that the metabolism of PIP
 
3
 
 and
IP
 
3
 
 has physiological and pathophysiological significance for
immune system regulation (for reviews see references 11–15).
Phosphatidylinositol 4, 5-bisphosphate [PI(4,5)P
 
2
 
] is a
substrate shared by PI3K and PLC. Phosphorylation of
PI(4,5)P
 
2
 
 by PI3K generates PIP
 
3
 
, which controls the intra-
cellular localization and activity of several proteins containing
pleckstrin homology domains (16). Conversely, hydrolysis of
PI(4,5)P
 
2
 
 by PLC produces IP
 
3
 
 and DAG, second messen-
gers necessary for the entry of calcium into cells and protein
kinase C activation, respectively (13). In addition to its well-
established role as a precursor of second messengers, a more
direct function for PI(4,5)P
 
2
 
 in the control of diverse cellular
processes has been demonstrated recently (17–20). Based on
biochemical assays and studies of permeable cell preparations,
PI(4,5)P
 
2
 
 appears to be particularly important for the regula-
tion of cytoskeletal reorganization and intracellular mem-
brane transport (9, 17, 18, 21–23).
The phosphatidylinositol phosphate kinases (PIPKs) are
enzymes important for PI(4,5)P
 
2
 
 synthesis. There are two
types of PIPKs: type I (PIPKI) and type II (PIPKII). Three
genes encode the 
 
 
 
,
 
 
 
 and 
 
 
 
 PIPKI isoforms, and the 
 
 
 
 gene
further generates three splice variants (24–28); in addition,
three genes encode PIPKII (29). PI(4,5)P
 
2
 
 can be synthesized
either by phosphorylation of PI(4)P by PIPKI, or by phos-
phorylation of PI(5)P by PIPKII. In mammalian cells, PI(4)P is
at least fifty times more abundant than PI(5)P. Moreover, PIPKI
(but not PIPKII) can induce dramatic changes in the actin cy-
toskeleton. Thus, it is generally accepted that the majority of
PI(4,5)P
 
2
 
 molecules in a mammalian cell are derived from
PIPKI-mediated phosphorylation of PI(4)P. Given the broad
range of potential functions of PI(4,5)P
 
2
 
, and the fact that the
steady-state level of PI(4,5)P
 
2
 
 is much higher than that of
other lipid second messengers, it is likely that some kind of
functional compartmentalization of PI(4,5)P
 
2
 
 production ex-
ists inside the cell (17, 30). Such compartmentalization could
be achieved by the interplay of multiple PIPKI molecules.
In this work, we genetically inactivated the 
 
 
 
 isozyme of
PIPKI (PIPKI
 
 
 
) in mice. PIPKI
 
 
 
 deficiency leads to en-
hanced degranulation and cytokine production in response
to Fc
 
 
 
RI stimulation in cultured mast cells. Moreover, ana-
phylactic responses are enhanced in mice deficient for PIP-
KI
 
 
 
. From a mechanistic standpoint, our results indicate that
PIPKI
 
 
 
 is crucial for the integrity of the actin cytoskeleton
and Fc
 
 
 
RI translocation to lipid rafts. Thus, our data are the
first genetic evidence for a nonredundant role of PIPKI
 
 
 
 in
vivo: the restraint of allergic reactions.
Figure 1. Gene targeting of murine PIPKI  and characterization of 
PIPKI  /  BMMCs. (A) Partial restriction map of the genomic PIPKI  
sequence and construction of the targeting vector bearing the neomycin 
resistance (Neor) gene. Exon 3, which encodes a portion of the kinase core 
domain, was replaced with a PGK-Neo cassette. The PIPKI  flanking probe 
used for Southern blotting and expected fragment sizes after digestion of 
WT and mutant genomic DNA are indicated. H, Hind III; E, EcoRV; S, SmaI; 
DT-A, diphtheria toxin A subunit. (B) Southern blot of genomic DNA from 
wild type (   ), PIPKI     (   ), and PIPKI     (   ) E14 embryonic 
stem cells hybridized to the probe indicated in A. (C) Western blot of PIPKI 
isozyme expression in BMMCs using antibodies specifically recognizing 
the indicated proteins. (D) Flow cytometric analysis of the normal surface 
expression of c-Kit (left) and Fc RI (right) on PIPKI     BMMCs. (E) Equiv-
alent cumulative cell numbers of PIPKI     (open circles) and PIPKI     
BMMCs (closed circles, dotted line) in cultures maintained for the indicated 
number of days. For all figures, results shown are representative of at least 
three independent experiments using three pairs of simultaneously estab-
lished PIPKI     and PIPKI     BMMCs.JEM VOL. 201, March 21, 2005 861
ARTICLE
RESULTS
Generation of PIPKI  knockout mice and bone marrow–
derived mast cells
Murine embryonic stem cells heterozygous for a deletion
mutation of the PIPKI  gene were generated by replacing
1.7 kb of the PIPKI  gene (including the region encoding
the NH2-terminal amino acids 68–106, indispensable for ki-
nase activity) with a PGK-Neo cassette (Fig. 1 A). Southern
blot analysis using a short arm flanking probe confirmed dis-
ruption of the gene (Fig. 1 B). No random integrations of
the  PGK-Neo cassette were detected (unpublished data).
These cells were used to derive homozygous PIPKI    
mice, which were born at the expected Mendelian ratio,
were healthy and fertile, and displayed no histological abnor-
malities up to 12 mo of age. There were no overt differences
from the WT in lymphocyte numbers or in subpopulations
present in the thymus, lymph node, spleen, and bone mar-
row (unpublished data).
It has been demonstrated that the PI3Ks and PLC ,
which utilize PI(4,5)P2 as a substrate to generate either PIP3
or IP3, respectively, play critical roles in the development
and effector functions of mast cells (31–34). In addition,
PI(4,5)P2 modulates the organization of the actin cytoskele-
ton, another cellular process that has been implicated in the
Figure 2. Enhanced Fc RI-mediated degranulation and calcium 
mobilization in PIPKI  /  mast cells. (A) Increased  -hexosaminidase 
release. PIPKI     (WT; open circles) and PIPKI     (closed circles) BMMCs 
were preloaded with mouse anti-DNP IgE and stimulated with 50 ng/ml 1 
DNP-HSA for the indicated times (left) or stimulated for 10 min with the 
indicated concentrations of DNP-HSA (right). The percentage of total 
cellular  -hexosaminidase that was released was taken as degranulation. 
Data shown are the mean   SD of triplicate samples. **, P   0.01 for 
PIPKI     cells compared with PIPKI     cells, as determined by
Student’s t test. (B) Increased calcium mobilization. IgE-sensitized, Fura-2-
loaded BMMCs were stimulated with 50 ng/ml 1 DNP-HSA and Ca2  flux 
was monitored by spectrofluorimetry. (C) Restoration of normal degranu-
lation and Ca2  flux after introduction of PIPKI  cDNA. Degranulation 
(left) and Ca2  flux (right) were measured as in A and B, respectively, in WT 
BMMCs or PIPKI     BMMCs reconstituted with either empty vector (red) 
or PIPKI  cDNA (blue).PIPKI  REGULATES ANAPHYLAXIS | Sasaki et al. 862
degranulation response (35, 36). To investigate the physio-
logical role of PIPKI  in mast cells, we established IL-3–
dependent bone marrow–derived mast cell (BMMC) lines
from PIPKI     and PIPKI     littermates. BMMCs from
PIPKI     mice lacked PIPKI  protein, but showed normal
expression of two other PIPKIs, PIPKI  and PIPKI  (Fig.
1 C). Both PIPKI     and PIPKI     BMMCs expressed
similar levels of c-Kit and Fc RI, markers that are character-
istic of mature BMMCs (Fig. 1 D), and PIPKI     BMMCs
proliferated at the WT rate (Fig. 1 E). Thus, PIPKI  expres-
sion appears to be dispensable for the cytokine-dependent
emergence and differentiation of BMMCs.
Enhanced degranulation, cytokine gene expression, and 
Fc RI signaling in PIPKI  /  BMMCs
To determine whether PIPKI  was required for mast cell
functions, we investigated mast cell granule release by mea-
suring the extracellular activity of  -hexosaminidase, a
marker enzyme for histamine-containing granules. The total
activity of  -hexosaminidase per cell did not differ between
PIPKI     and PIPKI     BMMCs, and treatment with
IgE alone did not induce granule release from BMMCs of
either genotype. However, Fc RI-evoked degranulation
was increased in PIPKI -deficient mast cells compared with
WT controls (Fig. 2 A). From a total of  15 experiments
using five pairs of BMMC lines from littermate mice, we
calculated that the degranulation at 5 min after 10 ng/ml
DNP stimulation was 56.7%   6.2 for PIPKI     BMMCs
compared with 23.2%   3.6 for WT BMMCs. This differ-
ence was statistically significant as determined by the Mann-
Whitney’s U test (P   0.00078) and suggested that PIPKI 
is involved in the control of Fc RI signaling.
It is well known that a transient increase in intracellular
calcium is essential for degranulation (34, 37). We found that
Figure 3. Augmented cytokine gene expression and Fc RI signaling 
in PIPKI  /  BMMCs. (A) Increased cytokine mRNA expression. PIPKI     
and PIPKI     BMMCs were sensitized with IgE and stimulated with DNP 
(50 ng/ml 1) for the indicated times. Induction of mRNA expression for the 
indicated cytokines was detected by RT-PCR. (B) Enhanced signaling mole-
cule phosphorylation after Fc RI cross-linking. BMMCs were sensitized 
with IgE and stimulated with DNP for the indicated times. For both panels, 
30  g of cell lysates were subjected to successive rounds of immunoblotting 
using phospho-specific and total antibodies recognizing the indicated 
proteins. Syk phosphorylation was monitored by immunoprecipitation of 
Syk followed by immunoblotting using antiphosphotyrosine antibody. 
One trial representative of a minimum of three experiments is shown in 
each case. White lines indicate that intervening lanes have been spliced out. 
(C) Band intensities in B were quantified using Dolphin-1 software, and 
relative phosphorylation levels were normalized to protein levels as described 
in Materials and methods. Values shown are the fold increase in the phos-
phorylated form of each molecule in PIPKI     BMMCs compared with 
the value in WT cells activated for 2 min (except for SAPK, which was 10 min). 
(D) Normal signaling molecule phosphorylation after IL-3 or SCF stimula-
tion. WT and PIPKI     BMMCs were stimulated with either 30 ng/ml 1 
IL-3 or 30 ng/ml 1 SCF and the phosphorylation of ERK and p38 was 
assessed as in B.JEM VOL. 201, March 21, 2005 863
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the amplitude of Ca2  elevation was increased in PIPKI    
BMMCs compared with that in WT cells (Fig. 2 B), consis-
tent with the enhanced degranulation observed in the mu-
tant cells. To confirm that the enhanced degranulation truly
resulted from the loss of PIPKI  expression, we reestablished
PIPKI  expression in PIPKI     BMMCs using retroviral
infection. Degranulation and Ca2  mobilization were re-
stored to normal by infection of PIPKI     BMMCs with a
retrovirus containing PIPKI , but not by infection with a
control virus (Fig. 2 C). Together, these results demonstrate
that a lack of PIPKI  expression engenders increased anti-
gen-induced degranulation mediated by high affinity Fc RI.
Cytokines produced by mast cells are critical mediators in
allergy and inflammation. Therefore, we investigated whether
PIPKI  played a role in mast cell cytokine production. Quan-
titative RT-PCR was performed to determine the induction
of various cytokine mRNA transcripts in WT and PIPKI    
BMMCs. Fc RI engagement induced higher levels of all cy-
tokine mRNAs examined in PIPKI     BMMCs compared
with WT cells (Fig. 3 A). IL-2 and IL-3 were the molecules
most markedly affected; relative quantitation revealed  50-
fold increases in these mRNAs in PIPKI     cells that had
been stimulated for 1 h (Fig. 3 A and not depicted).
Cytokine gene expression is regulated by several sig-
naling cascades, including those governed by mitogen-acti-
vated protein kinases (38). We stimulated PIPKI     and
PIPKI     BMMCs with IgE plus antigen and monitored
the phosphorylation (activation) of various signaling pro-
teins. Fc RI-triggered phosphorylation of ERK1/ERK2
(T202/Y204), SAPK (T183/Y185), p38 (T180/Y182),
PLC -1 (Y783), PKB (Ser473), and Syk was increased in
PIPKI     BMMCs compared with WT BMMCs (Fig. 3, B
and C), indicating that multiple signaling cascades are acti-
vated in the absence of PIPKI . Of interest, normal phos-
phorylation of ERK and p38 occurred in PIPKI     BM-
MCs stimulated with either IL-3 or SCF (Fig. 3 D), and the
basal phosphorylation of mitogen-activated protein kinases
was not increased in PIPKI     BMMCs (Fig. 3, B and D).
Therefore, an absence of PIPKI  does not lead to hy-
perphosphorylation of these signaling molecules per se.
Rather, the hyperphosphorylation of signaling molecules in
PIPKI     BMMCs depends on Fc RI stimulation.
Increased severity of local and systemic anaphylactic 
reactions in PIPKI -deficient mice
Anaphylaxis is an extreme form of allergic reaction triggered
by allergen-induced cross-linking of allergen-specific IgE
present on the surface of mast cells. Mast cell degranulation
is induced, which leads to the release of copious amounts of
vasoactive amines and inflammatory mediators. To deter-
mine whether PIPKI  functions as a negative regulator of
mast cell activation in vivo, we examined IgE-dependent
anaphylactic reactions in PIPKI     mice. Antigen chal-
lenge of mice that had been sensitized previously with
monoclonal DNP-specific IgE antibody demonstrated that
PIPKI     mice exhibited a greater degree of systemic ana-
phylaxis than WT mice, as assessed by core temperature
changes (Fig. 4 A). An increase in passive cutaneous anaphy-
laxis was also observed in the mutants (Fig. 4 B). Mast cell
numbers were identical in the ear skin of WT (12   0.9 per
field; n   8) and PIPKI     (12   1.0 per field; n   8)
mice, so that the augmented anaphylaxis in PIPKI     mice
was most likely due to mast cell hyperreactivity to antigens.
These data imply that a major physiological role of PIPKI 
is to prevent inappropriate mast cell degranulation and cyto-
kine production and, thus, anaphylaxis.
Decreased PI(4,5)P2 levels and atypical actin cytoskeleton in 
PIPKI -deficient mast cells
In view of the in vitro evidence that PIPKI  produces
PI(4,5)P2, the precursor of IP3 and PIP3, the finding of in-
Figure 4. Enhanced anaphylactic responses in PIPKI  /  mice. 
(A) Systemic anaphylaxis. WT and PIPKI     mice (n   7 mice per genotype) 
received 5  g anti-DNP IgE i.v., followed by stimulation with 1 mg DNP-
HSA per mouse. The systemic anaphylactic response was monitored by 
measuring rectal temperature at the indicated times after antigen injection. 
(B) Passive cutaneous anaphylaxis. WT and PIPKI     mice (n   9 per 
genotype) received 100  g anti-TNP IgE i.v. After 24 h, mice were epicuta-
neously challenged with 10  l 1% picryl chloride on the right ears, and with 
10  l 1% oxazolone on the left ears. Net ear swelling (thickness of the right 
ear minus that of the left ear) was measured with a caliper at the indicated 
times. Data are expressed as mean   SD. *, P   0.05 and **, P   0.01 for 
PIPKI     mice compared with PIPKI     mice as determined by
Student’s unpaired t test.PIPKI  REGULATES ANAPHYLAXIS | Sasaki et al. 864
Figure 5. PI(4,5)P2 levels and actin cytoskeleton in PIPKI  /  BMMCs. 
(A) Altered phospholipids. HPLC analysis of phospholipids prepared from 
WT and PIPKI     BMMCs that were metabolically labeled with [3H]inositol 
for 48 h. The chromatographic tracings shown are one result representative 
of five independent trials. The decrease in PI(4,5)P2 (0.84-fold) and increase 
in PI(4)P (1.13-fold) in PIPKI     BMMCs were statistically significant 
(insets). *, P   0.05 for PIPKI     cells compared with untreated WT cells. 
(B) Decreased F-actin content as determined by flow cytometry. IgE-sensitized 
PIPKI     BMMCs and IgE-sensitized WT BMMCs, which were either left 
untreated or pretreated with 0.5  M latrunculin (Latr) for 15 min, were 
stimulated with 50 ng/ml 1 DNP for the indicated times. F-actin was 
stained with Alexa 488–labeled phalloidin and analyzed by flow cytometry. 
The mean channel fluorescence (MCF) in untreated WT BMMCs was arbi-
trarily assigned a value of 100. Data shown are the mean percentage of 
the control value   SD of triplicate samples. *, P   0.05 for PIPKI     
cells or latrunculin-treated WT cells compared with untreated WT cells at 
the indicated times. (C) Decreased F-actin content as determined by con-
focal fluorescence microscopy. F-actin in the cells examined in B was visu-
alized using Alexa 488–labeled phalloidin. Confocal images were collected 
every 1  m, and summation images (top and middle rows) or single JEM VOL. 201, March 21, 2005 865
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creased mast cell activation and allergic reactions in the ab-
sence of PIPKI  was an unexpected result. Therefore, we
determined the relative contribution of PIPKI  to overall
PI(4,5)P2 production. The intracellular PI(4,5)P2 content
was assessed in BMMCs that had been metabolically labeled
with [3H]inositol for 48 h to achieve a stable equilibrium.
Lipid extraction followed by HPLC analysis revealed a statis-
tically significant decrease in PI(4,5)P2 in BMMCs lacking
PIPKI  (Fig. 5 A). A concomitant increase in PI(4)P, the
substrate of PIPKI , was observed in PIPKI     BMMCs.
These results provide the first genetic evidence that PIPKI 
acts as a functional PI(4)P 5-kinase in vivo, and are in agree-
ment with a recent paper describing a partial decrease in
PI(4,5)P2 levels in HeLa cells treated with small interference
RNA for PIPKI  (39). We conclude that the loss of PIPKI 
can be compensated for by other PIPKs in the context of
bulk PI(4,5)P2 synthesis, but that a specific PI(4,5)P2 pool
may exist that is exclusively maintained by PIPKI .
To gain insights into the functional characteristics of the
PI(4,5)P2 compartment controlled by PIPKI , we analyzed
the production of the PI(4,5)P2–derived second messenger
IP3. At 1 min after Fc RI stimulation, IP3 production was
enhanced in PIPKI     BMMCs (2.8   0.37 pmol/106)
compared with WT cells (2.1   0.17 pmol/106; P   0.13;
n   8). In addition, the observation that PKB activation was
increased in PIPKI     BMMCs (Fig. 3 B) suggests that
PIP3 formation is also enhanced in the absence of PIPKI .
Thus, somewhat surprisingly, the production of the second
messengers IP3 and PIP3 is increased, rather than decreased,
in the absence of PIPKI .
In sharp contrast, the absence of PIPKI  had a clearly
suppressive effect on the filamentous actin cytoskeleton
(F-actin) in BMMCs. F-actin in PIPKI     BMMCs was
consistently decreased to 70–80% of the WT level (Fig. 5 B).
We used confocal fluorescence microscopy to examine the
morphology and distribution of F-actin in PIPKI     BM-
MCs. A dramatic reduction in F-actin staining was found in
PIPKI     BMMCs in comparison with WT cells (Fig. 5 C).
Notably, the pattern of F-actin distribution and the cell
shape of PIPKI     BMMCs were similar to those of WT
BMMCs treated with latrunculin, a potent inhibitor of actin
polymerization (40). Cortical actin filaments were decreased
in both cases. Together, these results indicate that PIPKI  is
dispensable for IP3 and PIP3 production, but is a critical reg-
ulator of actin cytoskeletal reorganization.
A role for F-actin in the down-regulation of mast cell 
degranulation, but not cytokine expression
The peripheral actin cytoskeleton is essential for many biologi-
cal processes involving changes to the plasma membrane archi-
tecture (41, 42). In the rat basophilic leukemia (RBL) cell line,
it has been demonstrated that Fc RI-triggered actin polymer-
ization plays a negative regulatory role in degranulation, cyto-
kine production, and Ca2  elevation as well as in Fc RI signal-
ing (35, 43). To test whether F-actin was involved in BMMC
responses, we first examined the effect of latrunculin on de-
granulation. WT BMMCs pretreated with latrunculin showed
enhanced degranulation in response to Fc RI engagement
(Fig. 5 D). Moreover, jasplakinolide, a cell-permeable stabilizer
of actin filaments, suppressed degranulation in BMMCs upon
Fc RI cross-linking (Fig. 5 E). Latrunculin and jasplakinolide
also had parallel effects on BMMC degranulation induced by
ionomycin (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20041891/DC1). These results suggest that
polymerized actin can restrain degranulation, and that the aug-
mented degranulation observed in PIPKI     BMMCs can be
attributed to their decreased polymerized actin content.
Next, we examined the possible involvement of the actin
cytoskeleton in Fc RI-mediated cytokine production and pro-
tein phosphorylation. Contrary to its striking effect on degran-
ulation, treatment of WT BMMCs with latrunculin before
Fc RI cross-linking did not enhance cytokine induction or
phosphorylation of signaling proteins, and did not lead to ele-
vated intracellular calcium (Fig. 5 F). These observations may
account for the fact that latrunculin only partially mimics the
effect of PIPKI  disruption on BMMC degranulation. Our
findings concur with a previous paper that demonstrated nor-
mal activation of ERK and p38 despite increased actin poly-
merization in BMMCs lacking Wiskott-Aldrich syndrome
protein-interacting protein (44). Thus, contrary to the situation
in RBL cells, alterations to the actin cytoskeleton in BMMCs
do not necessarily result in anomalies to all Fc RI-evoked cel-
lular responses. Rather, our data show that PIPKI -mediated
suppression of Fc RI-mediated cellular responses in mast cells
appears to operate via at least two different mechanisms, only
one of which depends on regulation of actin polymerization.
Increased localization of Fc RI in lipid rafts in PIPKI  /  
BMMCs
Although most Fc RI-mediated responses were potentiated
in PIPKI -deficient BMMCs, those induced by IL-3 and
images from the center of representative cells (bottom row) are presented. 
Bar, 10  m. The WT cells exhibited a more jagged circumferential F-actin 
structure compared with PIPKI     cells (arrowheads). (D) Increased 
degranulation induced by latrunculin. IgE-sensitized PIPKI     BMMCs, 
and IgE-sensitized WT BMMCs that were either left untreated or pretreated 
with latrunculin (Latr) for 15 min were stimulated with 50 ng/ml 1 DNP for 
the indicated times. Degranulation was measured as in Fig. 2 A. **, P   0.01 
for latrunculin-treated WT cells or PIPKI     cells compared with un-
treated WT cells at 5 min after cross-linking (n   4). (E) Suppression of 
degranulation induced by jasplakinolide. IgE-sensitized PIPKI     BMMCs 
that were either left untreated or pretreated with 1 M jasplakinolide 
(Jasp) for 15 min were stimulated with DNP for 5 min. Degranulation 
was assessed as for in D. (F) Normal cytokine mRNA expression, signaling 
molecule phosphorylation, and Ca2  mobilization in the presence of 
latrunculin. IgE-sensitized WT BMMCs that were either left untreated or 
pretreated with latrunculin for 15 min were stimulated with DNP for 
the indicated times. Cytokine gene expression, protein phosphorylation, 
and Ca2  mobilization were determined as in Fig. 3, A and B, and Fig. 
2 B, respectively.PIPKI  REGULATES ANAPHYLAXIS | Sasaki et al. 866
SCF treatment were similar in magnitude to those of WT
BMMCs. Therefore, we investigated whether an absence of
PIPKI  could lead to a change in the dynamics of Fc RI
distribution on the plasma membrane. Lipid rafts are defined
as plasma membrane microdomains enriched with glycosphin-
golipids and cholesterol. These structures are now generally
recognized as “signaling platforms” (45, 46). It has been
shown that, after cross-linking, Fc RI molecules are recruited
to the rafts where they undergo tyrosine-phosphorylation as
the initiation step of several downstream signaling cascades.
Indeed, disruption of lipid rafts with methyl- -cyclodextrin
inhibited Fc RI signaling in BMMCs, as exemplified by a de-
crease in ERK and p38 phosphorylation (Fig. S2, available at
http://www.jem.org/cgi/content/full/jem.20041891/DC1).
Due to their low density, lipid rafts can be separated
from nonraft plasma membrane components by ultracentri-
fugation of detergent-lysed cells in sucrose density gradients.
As shown in Fig. 6 A, engagement of Fc RI induced trans-
location of at least the Fc RI  chain component of Fc RI
to the lipid raft fractions (fractions 3 and 4) of both WT and
PIPKI     BMMCs. Importantly, the presence of Fc RI 
in the raft fractions was significantly enhanced in PIPKI    
BMMCs even before aggregation. Immunoblotting for the
lipid raft marker linker for activation of T cells (LAT) dem-
onstrated that the partitioning of LAT between the lipid rafts
and nonlipid raft regions of the membrane was not altered in
the absence of PIPKI  (Fig. 6 B). It should also be noted
that the amounts of Fc RI  in the lipid rafts were not affected
by latrunculin, suggesting that the actin cytoskeleton does
not play a major role in regulating the redistribution of
Fc RI. These results suggest that PIPKI  suppresses the
interaction between Fc RI and the lipid rafts independently
of actin cytoskeletal organization. Such a role for PIPKI 
could explain its apparent ability to impede the propagation
of Fc RI-mediated signaling cascades leading to BMMC
cytokine production and degranulation. The precise mecha-
nism by which PIPKI  regulates Fc RI localization is under
investigation.
DISCUSSION
Mast cells play a key role in allergic reactions due to their
ability to synthesize and release proinflammatory mediators
and cytokines (1–3). Upon exposure to allergens, specific
IgE bound to Fc RI on mast cells becomes cross-linked and
intracellular signals are transduced that lead to cellular activa-
tion. These intracellular signals are tightly regulated, as spurious
signals could result in unwanted, and possibly deleterious, re-
sponses. Although recent work has identified many of the
proteins that positively regulate Fc RI signaling, little is
known about the negative regulators of these signaling cas-
Figure 6. Regulation of Fc RI localization to lipid rafts by PIPKI . 
(A) Enhanced localization of Fc RI  to lipid rafts. BMMCs sensitized with 
anti-DNP IgE were either left untreated or treated with latrunculin for 15 
min. Cells were incubated with or without DNP (stimulation) for 2 min, 
lysed in 0.5% Triton X-100 buffer, and subjected to sucrose gradient ul-
tracentrifugation to purify lipid rafts. (left) Fractions were separated by 
SDS-PAGE, transferred to PVDF membranes, and immunoblotted (IB) 
with anti-Fc RI  -chain antibody. Fractions 3 and 4 contain the lipid 
rafts. (right) The distribution of Fc RI  in fractions 3 and 4 was quanti-
tated by densitometric analysis of the immunoblot. (B) Normal distribu-
tion of LAT. Fractions from A were immunoblotted with anti-LAT anti-
body as for in A (right) and LAT distribution was densitometrically 
quantitated as in A (left).JEM VOL. 201, March 21, 2005 867
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cades. In this study, we have identified a physiological role
for PIPKI  as a negative regulator of Fc RI-mediated mast
cell functions. BMMCs from PIPKI -deficient mice exhibit
enhanced degranulation and cytokine gene expression. As a
result, loss of PIPKI  culminates in aggravated systemic and
local passive anaphylaxis in vivo.
PIPKIs are lipid kinases that are critical for intracellular
signaling due to their production of the versatile phospho-
lipid PI(4,5)P2. PIPKIs and PI(4,5)P2 have been implicated
in the regulation of the actin cytoskeleton, vesicular traf-
ficking, cell migration, adhesion, phagocytosis, and apopto-
sis (9, 17, 18, 21, 22). Three genes encoding PIPKIs have
been identified that show considerable homology to each
other, but not to other lipid kinases. However, it has been
difficult to clarify whether the multiple PIPKI isozymes
have overlapping or redundant functions. The genetic ex-
amination of PIPKI  function presented in this work
clearly demonstrates an essential function for a PIPKI
isozyme as a modifier of Fc RI-mediated mast cell activa-
tion, and suggests that each PIPKI isozyme may play a
unique physiological role. Consistent with this concept is
the recent paper by Di Paolo et al., which asserts that dis-
ruption of the PIPKI  isoform in mice leads to early post-
natal lethality and synaptic defects (47). However, there
must also be an overlap of PIPKI isozyme functions be-
cause PIPKI -deficient mice are viable and fertile and dis-
play no overt histological abnormalities despite the wide
tissue distribution of PIPKI  expression.
It has long been hypothesized that cortical actin filaments
act as a barrier to prevent secretory granules from accessing
the plasma membrane (48). This inference has been supported
mainly by pharmacological evidence that inhibitors of actin
polymerization potentiate degranulation. In vitro, latrunculin
reportedly enhances Fc RI-mediated degranulation in both
mouse BMMCs and RBL cells, although Fc RI stimulation
results in a decrease in F-actin content in the former (44) and
an increase in the latter (35). Thus, a major outstanding ques-
tion in this field has been whether this actin-based regulation
of degranulation operates physiologically. Our work shows
that PIPKI  regulates actin reorganization in mast cells in a
manner that is functionally important for degranulation, sup-
porting a physiologically relevant role for the control of de-
granulation via the actin cytoskeleton. Moreover, our results
provide insight into a potential molecular mechanism that can
maintain sufficient F-actin in mast cells to suppress inappro-
priate degranulation. This mechanism may define the thresh-
old for the occurrence of allergic reactions in vivo.
IP3 production and PIP3-dependent activation of PKB
are enhanced in PIPKI     BMMCs, suggesting that PIP-
KI  is dispensable for supplying PI(4,5)P2 for the generation
of second messengers. It has recently become clear that intact
PI(4,5)P2 (but not the products of its metabolism) can act di-
rectly as a signaling lipid (17–20). This function of PI(4,5)P2
is mediated by actin regulatory proteins and components of
the exocytosis/endocytosis machinery that possess PI(4,5)P2
binding domains (9, 17, 18, 21–23). Given the essential role
of PI(4,5)P2 in actin reorganization, our data indicate that
the pool of PI(4,5)P2 produced specifically by PIPKI  is re-
sponsible for the maintenance of the actin cytoskeleton in
mast cells. We propose that PI(4,5)P2 synthesis by PIPKI 
must take place in a defined membrane compartments be-
cause, despite its striking effect on F-actin content, the over-
all PI(4,5)P2 level was only partially reduced in BMMCs
lacking PIPKI  (Fig. 5). However, the putative specialized
membrane compartments in which PIPKI -mediated PI(4,5)P2
synthesis occurs remain to be characterized. It should also be
noted that our findings do not contradict previous studies
that have unequivocally demonstrated that PI(4,5)P2 inter-
acts with and activates several proteins needed for the dock-
ing and fusion of secretory granules (49, 50). Our work
suggests that, although PIPKs other than PIPKI  can supply
sufficient PI(4,5)P2 to allow membrane fusion, PIPKI  has
an exclusive role in modulating the actin cytoskeleton and
mast cell degranulation.
The mechanism underlying the augmented Fc RI sig-
naling response and increased cytokine gene expression
caused by PIPKI  deficiency appears to be distinct from
that underlying the enhanced degranulation because these
phenotypes could not be induced by latrunculin-mediated
reduction of F-actin. As PIPKI -deficient BMMCs re-
sponded normally to IL-3 and SCF, whereas virtually all
responses mediated by Fc RI were enhanced, we speculate
that PIPKI  acts at the level of Fc RI activation as well as
at the level of actin cytoskeleton reorganization. Recent
studies have revealed that LAT in lipid rafts plays a central
role in Fc RI signaling in mast cells (51). Aggregation of
Fc RI induces the inclusion of this receptor and Syk into
lipid rafts. Subsequently, Syk phosphorylates LAT to create
protein-binding sites that facilitate the assembly of a mac-
romolecular complex of signaling proteins that include
Grb2, Gads, SLP76, Vav, and PLC . Thus, the Fc RI sig-
naling pathway becomes broadly divergent after the stage
of lipid raft recruitment (36, 52, 53). In our work, we
showed that the association of the Fc RI  subunit with
lipid rafts was increased in PIPKI     BMMCs. Does the
distribution of Fc RI  fairly represent the distribution of
Fc RI? Although the Fc RI  chain associates with a vari-
ety of receptors, including Fc R (2), BMMCs do not de-
granulate in response to IgG (unpublished data). Further-
more, other receptors in which Fc RI  participates, such
as Fc R, are not expressed on BMMCs (2, 54). Therefore,
we believe that the distribution of Fc RI  truly represents
the localization of functional Fc RI on the mast cell surface.
To our knowledge, our investigation of PIPKI  provides
the first identification of a molecule that modulates the lo-
calization of Fc RI to lipid rafts. Thus, loss of this regula-
tory function may account for the broad impact of PIPKI 
deficiency on the multiple cellular responses elicited by
Fc RI engagement (Fig. 7). It should be noted that some
Fc RI-mediated responses are unaltered in the absence ofPIPKI  REGULATES ANAPHYLAXIS | Sasaki et al. 868
LAT (51), indicating that signaling pathways independent
of lipid rafts exist. The role of PIPKI  in such pathways re-
mains to be defined.
Our work provides clues to the mechanisms involved in
Fc RI dynamics in the plasma membrane. Because phos-
phoinositides (including PI(4,5)P2) are reportedly enriched
in lipid rafts (55), it will be interesting to analyze Fc RI dis-
tribution in mutant cells deficient for other phosphoinosi-
tide-metabolizing enzymes such as PIPKI  and PIPKI .
These types of studies may further establish that the
PI(4,5)P2 synthesized by each PIPK isozyme is functionally
compartmentalized. More importantly, such investigations
may clarify the precise mechanisms regulating Fc RI dy-
namics in the plasma membrane that influence the outcome
of allergen challenge in vivo.
Our findings may have applications in the clinical arena.
Fc RI engagement is known to trigger allergic reactions,
and an association between human Fc RI  chain polymor-
phisms and atopic phenotypes has been reported previously
(56). Fc RI engagement has also been linked to the patho-
genesis of parasitic diseases and autoimmune disorders (2).
These associations arise because Fc RI is found on mono-
cytes, eosinophils, platelets, Langerhans cells, and dendritic
cells as well as on mast cells. Thus, the functional specializa-
tion reported here for a PIPKI isoform in the molecular at-
tenuation of Fc RI signaling may represent a distinct mech-
anism underlying a subset of allergic hypersensitivities,
parasite susceptibilities or autoimmune diseases. Such spe-
cialization among PIPKs could provide clinical researchers
with novel therapeutic targets for these disorders.
MATERIALS AND METHODS
Generation of PIPKI -deficient mice. Mice deficient for PIPKI 
were generated using homologous recombination in embryonic stem cells as
described previously (57). For further experimental details, see Supplemental
Materials and methods (available at http://www.jem.org/cgi/content/full/
jem.20041891/DC1). All experimental protocols were reviewed and ap-
proved by the Akita University Institutional Committee for Animal Studies.
Retroviral gene transfer. BMMC reconstitution assays using the retroviral
vector pBabe-puro were performed as described previously (58). In brief, Myc
epitope-tagged full-length PIPKI  cDNA (59) was cloned into the SalI site of
pBabe-puro. This vector was transfected into a phoenix-E packaging cell line.
PIPKI     BMMCs were cultured in the supernatant for 1 d and selected in
2.5 mg/ml 1 puromycin for 3 wk before being used for experiments.
Degranulation and calcium mobilization. 2   106 cells ml 1 BMMCs
were sensitized with 0.2  g/ml 1 anti-DNP IgE (SPE-7) for 15 h. The cells
were washed, resuspended in OPTI-MEM (GIBCO BRL) containing 0.1%
BSA, and challenged with DNP-HSA (Sigma-Aldrich). The percentage of
total cellular  -hexosaminidase that was released was taken as degranulation
as described previously (60). For calcium mobilization, the sensitized BM-
MCs were incubated at room temperature for 45 min with 2  M Fura-2-
AM (Molecular Probes) in Tyrode’s buffer (10 mM Hepes, pH 7.4, 112
mM NaCl, 2.7 mM KCl, 0.4 mM NaH2PO4, 1.6 mM CaCl2, 1 mM
MgCl2, 2 mM glucose, and 1% BSA). Fc RI-mediated calcium mobiliza-
tion was measured every 0.5 s using a spectrophotometer (Shimadzu) set for
dual excitation at 340 and 380 nm and emission at 510 nm.
Immunoblotting, immunoprecipitation, and in vitro PI3K assay.
BMMCs were sensitized as described before. After washing and resuspension
in OPTI-MEM containing 0.1% BSA, the cells (5–10   106) were stimu-
lated with 50 ng ml 1 DNP-HSA. Reactions were terminated by the addi-
tion of ice-cold PBS and cell lysates were prepared in RIPA buffer (1% Triton
X-100, 10 mM Tris/HCl, pH 7.4, 150 mM NaCl, 30 mM Na4P2O7, 5 mM
EDTA, 50 mM NaF, 1 mM Na3VO4, and a protease inhibitor cocktail from
Roche Molecular Chemicals). Immunoprecipitation and immunoblotting
were performed as described previously (61). The relative phosphorylation of
each signaling protein was normalized to its protein level in each sample (for
details, see Supplemental Materials and methods). Immune complex lipid
kinase assays were performed as described previously (57).
Passive systemic and cutaneous anaphylaxis. For passive systemic ana-
phylaxis, mice (10–15 wk old) were sensitized for 24 h by intravenous injec-
tion of 5  g anti-DNP IgE (SPE-7). The mice were subsequently challenged
with an intravenous injection of 100  g DNP-HSA. Body temperature was
monitored using a rectal probe (Shibaura) starting from the time of antigen
injection. For passive cutaneous anaphylaxis, mice (10–15 wk old) were in-
jected intravenously with 100  g anti-TNP IgE (62). After 24 h, ear-swelling
responses were elicited by painting 10  l 1% picryl chloride (Nakalai Tesque)
in acetone on the right ears of each animal, and 10  l 1% 4-ethoxymethylene-
2-phenyl-2-oxazoline-5-one (oxazolone; Sigma-Aldrich) in acetone on the
left ear. Ear thickness was measured as described previously (62).
Cellular PI(4,5)P2 measurement and actin cytoskeleton assess-
ments. BMMCs were labeled for 48 h with 10  Ci ml 1 [3H]-myo-inosi-
tol (Amersham Biosciences) in inositol-free DMEM containing dialyzed
10% heat-inactivated FCS. Labeling was quenched and lipids were ex-
tracted as described (57). Dried lipids were deacylated and analyzed by
HPLC according to Serunian et al. using a Partisphere SAX column (What-
man; reference 63). Radioactivity was assayed in 0.5-ml fractions using a
liquid scintillation counter. To compare data among experiments, the raw
radioactive counts determined for PI(4)P and PI(4,5)P2 were normalized to
the raw radioactive counts for total phosphoinositides. The normalized
amounts of PI(4)P or PI(4,5)P2 present in PIPKI     BMMCs in each ex-
periment were assigned a value of 1, and the relative amounts of PI(4)P or
Figure 7. A model for the role of PIPKI  in mast cell activation and 
anaphylactic responses mediated by Fc RI. PIPKI  acts both to control 
Fc RI signaling after cross-linking and to promote actin polymerization, 
thereby inhibiting both degranulation and cytokine production. Thus, ana-
phylaxis is prevented.JEM VOL. 201, March 21, 2005 869
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PI(4,5)P2 in PIPKI     BMMCs were calculated. Significance was assessed
with Student’s t test. p-values  0.05 were considered significant. Flow cy-
tometry and fluorescence microscopy were used to analyze the status of the
actin cytoskeleton (for details, see Supplemental Materials and methods).
RT-PCR. 107 BMMCs sensitized with anti-DNP IgE were stimulated
with 50 ng ml 1 DNP-HSA. Total RNA was prepared using TRIzol re-
agent (GIBCO BRL), and first-strand cDNA was synthesized using 5  g
total RNA with M-MLV Reverse Transcriptase (Toyobo). Specific PCR
primers and amplification conditions for cytokine gene expression are de-
scribed in Supplemental Materials and methods.
Lipid raft preparation. Preparation of lipid rafts was performed as de-
scribed previously with some modifications (64). In brief, 2   107 BMMCs
sensitized with anti-DNP IgE were incubated for 2 min at 37 C with or
without DNP. Cells were washed and pellets were lysed in 1 ml MBS
buffer (0.5% Triton X-100, 25 mM MES, pH 6.5, 150 mM NaCl, 1 mM
Na3VO4, and protease inhibitor cocktail) and incubated for 30 min on ice.
Subsequent steps were performed at 4 C. Lysates were mixed with 0.5 ml
85% sucrose in MBS, transferred to 5PA centrifuge tubes (Hitachi), and
overlaid with 2.4 ml 35% sucrose followed by 1.5 ml 5% sucrose. After cen-
trifugation for 18 h at 200,000 g in a Hitachi P55ST2 rotor at 4 C, 10 0.5-
ml fractions were collected starting at the top of the gradient. For analysis of
protein composition, aliquots were mixed directly with 4  SDS-PAGE
sample buffer and analyzed by Western blotting. Distribution of Fc RI and
LAT in lipid rafts was determined by densitometric analysis of immunoblots
using Dolphin-1D software (Kurabo).
Online supplemental material. Primers used for cytokine gene expres-
sion and procedures for the generation of PIPKI -deficient mice and the
analysis of Fc RI surface expression, actin cytoskeleton assessments, and im-
munoblotting are available in Supplemental Materials and methods. Fig. S1
shows the effects of latrunculin and jasplakinolide on ionomycin-induced
degranulation in WT and PIPKI     BMMCs. Fig. S2 shows methyl- -
cyclodextrin inhibition of Fc RI-mediated activation of p38 and ERK.
Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20041891/DC1.
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